⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 1998Journal of Clinical Oncology

Peripheral T-cell lymphoma after anti-CD20 antibody therapy.

Scott A. Tetreault S L Abler Bruce A. Robbins Alan Saven

View at Publisher

Ask AI

Bookmark

Share

Abstract

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.4.1635 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9552080 Peripheral T-cell lymphoma after anti-CD20 antibody therapy. S TetreaultxS TetreaultSearch for articles by this author , S L AblerxS L AblerSearch for articles by this author , B RobbinsxB RobbinsSearch for articles by this author , A SavenxA SavenSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.4.1635 First Page PDF © 1998 by American Society of Clinical Oncology

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tetreault et al. (1998) studied this question.

synapsesocial.com/papers/6ab86c98715783b94cba9f9e https://doi.org/10.1200/jco.1998.16.4.1635

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Art as a Shared Space: Tracing the Unseen Through a Body MapJournal of Clinical Oncology · 2026
2PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0Journal of Clinical Oncology · 2026
3Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 TrialJournal of Clinical Oncology · 2026
4COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract CancerJournal of Clinical Oncology · 2026
5Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final AnalysisJournal of Clinical Oncology · 2026

ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate CancerJournal of Clinical Oncology · 2026
Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast CancerJournal of Clinical Oncology · 2026
Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III TrialJournal of Clinical Oncology · 2026
Effectiveness of a Multisite Oncology Financial Navigation Intervention: The Lessening the Impact of Financial Toxicity Clinical TrialJournal of Clinical Oncology · 2026
First-In-Human Study of 211 At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic MalignanciesJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology